{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T21:42:37Z","timestamp":1788298957237,"version":"build-2803163510"},"reference-count":163,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Epigenetic dysregulation is increasingly recognized as a key driver of glioblastoma (GBM), with bromodomain-containing protein 4 (BRD4) emerging as a critical regulator of tumor malignancy. GBM is an aggressive brain tumor marked by diffuse infiltration, a population of stem-like cells and multiple resistance mechanisms, which together render it largely incurable. Standard treatment, consisting of surgical resection followed by radiotherapy and temozolomide chemotherapy, confers only limited therapeutic benefit, while a member of the bromodomain and extra-terminal (BET) family, BRD4, regulates transcriptional programs essential for oncogene activation, chromatin stability and glioma cell survival. Its expression is markedly elevated in GBM relative to normal brain tissue, implicating BRD4 in tumor initiation, progression and therapeutic resistance. Recent advances have enabled the development of selective BRD4 inhibitors and degraders capable of penetrating the blood\u2013brain barrier and preferentially targeting glioma cells. Preclinical and early-phase clinical studies indicate that these agents suppress tumor growth and may enhance the efficacy of existing treatments. Although BRD4 clearly influences glioma progression and modulates key oncogenic pathways, the precise mechanisms underlying BRD4-driven gliomagenesis remain only partially understood. Ongoing research continues to advance knowledge of its multifaceted functions. This review summarizes current knowledge on BRD4 in GBM, evaluates emerging BRD4-targeted therapeutic strategies and outlines major challenges and future directions for clinical translation.<\/jats:p>","DOI":"10.3390\/ijms27052268","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T10:24:34Z","timestamp":1772447074000},"page":"2268","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Targeting BRD4\u2014A Promising Therapeutic Option for Glioblastoma?"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9230-1639","authenticated-orcid":false,"given":"Maria","family":"Lindner","sequence":"first","affiliation":[{"name":"The Student Scientific Society Biomolekularni, Poznan University of Medical Sciences, 60-806 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7807-5964","authenticated-orcid":false,"given":"Dagmara","family":"Lisi\u0144ska","sequence":"additional","affiliation":[{"name":"The Student Scientific Society Biomolekularni, Poznan University of Medical Sciences, 60-806 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8030-5247","authenticated-orcid":false,"given":"Anna","family":"K\u0119dzierzy\u0144ska","sequence":"additional","affiliation":[{"name":"The Student Scientific Society Biomolekularni, Poznan University of Medical Sciences, 60-806 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2872-8875","authenticated-orcid":false,"given":"Aleksandra","family":"Majchrzak-Celi\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Biochemistry, Poznan University of Medical Sciences, Rokietnicka 3, 60-806 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Grochans, S., Cybulska, A.M., Simi\u0144ska, D., Korbecki, J., Kojder, K., Chlubek, D., and Baranowska-Bosiacka, I. (2022). Epidemiology of Glioblastoma Multiforme\u2013Literature Review. Cancers, 14.","DOI":"10.3390\/cancers14102412"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1001\/jama.2023.0023","article-title":"Glioblastoma and Other Primary Brain Malignancies in Adults: A Review","volume":"329","author":"Schaff","year":"2023","journal-title":"JAMA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1093\/nop\/npad070","article-title":"Glioblastoma in the Oldest Old: Clinical Characteristics, Therapy, and Outcome in Patients Aged 80 Years and Older","volume":"11","author":"Stadler","year":"2024","journal-title":"Neuro-Oncol. Pract."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jocn.2018.05.002","article-title":"Ten-Year Survival in Glioblastoma. A Systematic Review","volume":"54","author":"Tykocki","year":"2018","journal-title":"J. Clin. Neurosci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s11060-020-03451-6","article-title":"Trends in Glioblastoma: Outcomes over Time and Type of Intervention: A Systematic Evidence Based Analysis","volume":"147","author":"Wijesekera","year":"2020","journal-title":"J. Neurooncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1159\/000531319","article-title":"Glioblastoma Multiforme: The Latest Diagnostics and Treatment Techniques","volume":"108","author":"Czarnywojtek","year":"2023","journal-title":"Pharmacology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1101\/gad.324301.119","article-title":"Glioblastoma Stem Cells: Lessons from the Tumor Hierarchy in a Lethal Cancer","volume":"33","author":"Gimple","year":"2019","journal-title":"Genes Dev."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Mattei, V., Santilli, F., Martellucci, S., Delle Monache, S., Fabrizi, J., Colapietro, A., Angelucci, A., and Festuccia, C. (2021). The Importance of Tumor Stem Cells in Glioblastoma Resistance to Therapy. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22083863"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1172\/JCI89587","article-title":"Overcoming Therapeutic Resistance in Glioblastoma: The Way Forward","volume":"127","author":"Osuka","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"El Khayari, A., Bouchmaa, N., Taib, B., Wei, Z., Zeng, A., and El Fatimy, R. (2022). Metabolic Rewiring in Glioblastoma Cancer: EGFR, IDH and Beyond. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.901951"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jocn.2015.05.066","article-title":"TERT Mutation in Glioma: Frequency, Prognosis and Risk","volume":"26","author":"Yuan","year":"2016","journal-title":"J. Clin. Neurosci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1038\/onc.2016.493","article-title":"Characterization of PTEN Mutations in Brain Cancer Reveals That Pten Mono-Ubiquitination Promotes Protein Stability and Nuclear Localization","volume":"36","author":"Yang","year":"2017","journal-title":"Oncogene"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1245\/s10434-013-3380-0","article-title":"Gain of Function of Mutant TP53 in Glioblastoma: Prognosis and Response to Temozolomide","volume":"21","author":"Wang","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11060-025-05049-2","article-title":"Do the Benefits of IDH Mutations in High-Grade Glioma Persist beyond the First Recurrence? A Multi-Institutional Retrospective Analysis","volume":"174","author":"Lally","year":"2025","journal-title":"J. Neurooncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.semcancer.2020.12.015","article-title":"Epigenetics of Glioblastoma Multiforme: From Molecular Mechanisms to Therapeutic Approaches","volume":"83","author":"Uddin","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.cell.2007.01.029","article-title":"The Epigenomics of Cancer","volume":"128","author":"Jones","year":"2007","journal-title":"Cell"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/s41416-020-0907-6","article-title":"BRD4 Promotes Metastatic Potential in Oral Squamous Cell Carcinoma through the Epigenetic Regulation of the MMP2 Gene","volume":"123","author":"Yamamoto","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_18","unstructured":"De Vleeschouwer, S. (2017). Epigenetic Mechanisms of Glioblastoma, Codon Publications."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13046-020-01643-6","article-title":"The Application of Histone Deacetylases Inhibitors in Glioblastoma","volume":"39","author":"Chen","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e495","DOI":"10.1002\/mco2.495","article-title":"Epigenetic Regulation in Cancer","volume":"5","author":"Gu","year":"2024","journal-title":"MedComm"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Majchrzak-Celi\u0144ska, A., Warych, A., and Szoszkiewicz, M. (2021). Novel Approaches to Epigenetic Therapies: From Drug Combinations to Epigenetic Editing. Genes, 12.","DOI":"10.3390\/genes12020208"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Bouyahya, A., Mechchate, H., Oumeslakht, L., Zeouk, I., Aboulaghras, S., Balahbib, A., Zengin, G., Kamal, M.A., Gallo, M., and Montesano, D. (2022). The Role of Epigenetic Modifications in Human Cancers and the Use of Natural Compounds as Epidrugs: Mechanistic Pathways and Pharmacodynamic Actions. Biomolecules, 12.","DOI":"10.3390\/biom12030367"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Lara-Ure\u00f1a, N., and Garc\u00eda-Dom\u00ednguez, M. (2021). Relevance of BET Family Proteins in SARS-CoV-2 Infection. Biomolecules, 11.","DOI":"10.3390\/biom11081126"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41392-020-00384-4","article-title":"The BET Family in Immunity and Disease","volume":"6","author":"Wang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Colardo, M., Gargano, D., Russo, M., Petraroia, M., Pensabene, D., D\u2019Alessandro, G., Santoro, A., Limatola, C., Segatto, M., and Di Bartolomeo, S. (2023). Bromodomain and Extraterminal Domain (BET) Protein Inhibition Hinders Glioblastoma Progression by Inducing Autophagy-Dependent Differentiation. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24087017"},{"key":"ref_26","first-page":"e620","article-title":"Bromodomain Inhibitor Review: Bromodomain and Extra-Terminal Family Protein Inhibitors as a Potential New Therapy in Central Nervous System Tumors","volume":"8","author":"Wadhwa","year":"2016","journal-title":"Cureus"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"106767","DOI":"10.1016\/j.phrs.2023.106767","article-title":"BRD4: New Hope in the Battle against Glioblastoma","volume":"191","author":"Duan","year":"2023","journal-title":"Pharmacol. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omto.2021.03.005","article-title":"BRD4: An Emerging Prospective Therapeutic Target in Glioma","volume":"21","author":"Yang","year":"2021","journal-title":"Mol. Ther.-Oncolytics"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"E5086","DOI":"10.1073\/pnas.1712363115","article-title":"Targetable BET Proteins- and E2F1-Dependent Transcriptional Program Maintains the Malignancy of Glioblastoma","volume":"115","author":"Xu","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1158\/1078-0432.CCR-12-3066","article-title":"Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma","volume":"19","author":"Cheng","year":"2013","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Taniguchi, Y. (2016). The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins. Int. J. Mol. Sci., 17.","DOI":"10.20944\/preprints201610.0100.v1"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"101794","DOI":"10.1016\/j.jbc.2022.101794","article-title":"Degradation and Inhibition of Epigenetic Regulatory Protein BRD4 Exacerbate Alzheimer\u2019s Disease-Related Neuropathology in Cell Models","volume":"298","author":"Zhang","year":"2022","journal-title":"J. Biol. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"BSR20211812","DOI":"10.1042\/BSR20211812","article-title":"The Paradigm of Drug Resistance in Cancer: An Epigenetic Perspective","volume":"42","author":"Adhikari","year":"2022","journal-title":"Biosci. Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"102670","DOI":"10.1016\/j.rechem.2025.102670","article-title":"Current Landscape of BRD4 Inhibitors: Selective Targeting and Protein Degradation for Enhanced Efficacy","volume":"18","author":"Deng","year":"2025","journal-title":"Results Chem."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Ali, H.A., Li, Y., Bilal, A.H.M., Qin, T., Yuan, Z., and Zhao, W. (2022). A Comprehensive Review of BET Protein Biochemistry, Physiology, and Pathological Roles. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.818891"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"128","DOI":"10.18231\/j.jdpo.2020.027","article-title":"Role of BRD4 in Cancer\u2014A Review","volume":"5","author":"Samani","year":"2020","journal-title":"IP J. Diagn. Pathol. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1080\/21541264.2022.2108302","article-title":"BRD4: A General Regulator of Transcription Elongation","volume":"13","author":"Altendorfer","year":"2022","journal-title":"Transcription"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/nsmb.2912","article-title":"BRD4 Assists Elongation of Both Coding and Enhancer RNAs by Interacting with Acetylated Histones","volume":"21","author":"Kanno","year":"2014","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Hajmirza, A., Emadali, A., Gauthier, A., Casasnovas, O., Gressin, R., and Callanan, M. (2018). BET Family Protein BRD4: An Emerging Actor in NF\u03baB Signaling in Inflammation and Cancer. Biomedicines, 6.","DOI":"10.3390\/biomedicines6010016"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1074\/jbc.RA119.010679","article-title":"Comparative Structure-Function Analysis of Bromodomain and Extraterminal Motif (BET) Proteins in a Gene-Complementation System","volume":"295","author":"Werner","year":"2020","journal-title":"J. Biol. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Cheung, K.L., Kim, C., and Zhou, M.-M. (2021). The Functions of BET Proteins in Gene Transcription of Biology and Diseases. Front. Mol. Biosci., 8.","DOI":"10.3389\/fmolb.2021.728777"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Morgado-Pascual, J.L., Rayego-Mateos, S., Tejedor, L., Suarez-Alvarez, B., and Ruiz-Ortega, M. (2019). Bromodomain and Extraterminal Proteins as Novel Epigenetic Targets for Renal Diseases. Front. Pharmacol., 10.","DOI":"10.3389\/fphar.2019.01315"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.molcel.2014.05.016","article-title":"The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition","volume":"54","author":"Shi","year":"2014","journal-title":"Mol. Cell"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"E159","DOI":"10.1073\/pnas.1102140108","article-title":"Bromodomain Protein Brd3 Associates with Acetylated GATA1 to Promote Its Chromatin Occupancy at Erythroid Target Genes","volume":"108","author":"Lamonica","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/s41392-023-01647-6","article-title":"Bromodomain and Extraterminal (BET) Proteins: Biological Functions, Diseases and Targeted Therapy","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Ijaz, T., and Burke, M.A. (2021). BET Protein-Mediated Transcriptional Regulation in Heart Failure. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22116059"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Li, G., Ma, L., Feng, C., Yin, H., Bao, J., Wu, D., Zhang, Z., Li, X., Li, Z., and Yang, C. (2024). MZ1, a BRD4 Inhibitor, Exerted Its Anti-Cancer Effects by Suppressing SDC1 in Glioblastoma. BMC Cancer, 24.","DOI":"10.1186\/s12885-024-11966-8"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/med.21730","article-title":"Inhibitors of Bromodomain and Extra-terminal Proteins for Treating Multiple Human Diseases","volume":"41","author":"Kulikowski","year":"2021","journal-title":"Med. Res. Rev."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/s41420-023-01775-6","article-title":"Super-Enhancers and the Super-Enhancer Reader BRD4: Tumorigenic Factors and Therapeutic Targets","volume":"9","author":"Qian","year":"2023","journal-title":"Cell Death Discov."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","article-title":"Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers","volume":"153","author":"Hoke","year":"2013","journal-title":"Cell"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"43137","DOI":"10.1074\/jbc.M112.413047","article-title":"Bromodomain-Containing Protein 4 (BRD4) Regulates RNA Polymerase II Serine 2 Phosphorylation in Human CD4+ T Cells","volume":"287","author":"Zhang","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1084\/jem.20190196","article-title":"Chromatin Landscapes Reveal Developmentally Encoded Transcriptional States That Define Human Glioblastoma","volume":"216","author":"Mack","year":"2019","journal-title":"J. Exp. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"10738","DOI":"10.1074\/jbc.M111.323493","article-title":"Bromodomain Protein Brd4 Associated with Acetylated Chromatin Is Important for Maintenance of Higher-Order Chromatin Structure","volume":"287","author":"Wang","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nsmb.3228","article-title":"BRD4 Is a Histone Acetyltransferase That Evicts Nucleosomes from Chromatin","volume":"23","author":"Devaiah","year":"2016","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1021\/cr500452k","article-title":"Protein Lysine Acetylation by P300\/CBP","volume":"115","author":"Dancy","year":"2015","journal-title":"Chem. Rev."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1128\/MCB.01020-07","article-title":"Brd4 Recruits P-TEFb to Chromosomes at Late Mitosis to Promote G1 Gene Expression and Cell Cycle Progression","volume":"28","author":"Yang","year":"2008","journal-title":"Mol. Cell. Biol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4899","DOI":"10.1091\/mbc.e09-05-0380","article-title":"Brd4 Marks Select Genes on Mitotic Chromatin and Directs Postmitotic Transcription","volume":"20","author":"Dey","year":"2009","journal-title":"Mol. Biol. Cell"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature09504","article-title":"Selective Inhibition of BET Bromodomains","volume":"468","author":"Filippakopoulos","year":"2010","journal-title":"Nature"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET Bromodomain Inhibition as a Therapeutic Strategy to Target C-Myc","volume":"146","author":"Delmore","year":"2011","journal-title":"Cell"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1126\/science.aab1433","article-title":"DRUG DEVELOPMENT. Phthalimide Conjugation as a Strategy for in Vivo Target Protein Degradation","volume":"348","author":"Winter","year":"2015","journal-title":"Science"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1126\/science.aaz8455","article-title":"Selective Targeting of BD1 and BD2 of the BET Proteins in Cancer and Immunoinflammation","volume":"368","author":"Gilan","year":"2020","journal-title":"Science"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41586-020-1930-8","article-title":"Selective Inhibition of the BD2 Bromodomain of BET Proteins in Prostate Cancer","volume":"578","author":"Faivre","year":"2020","journal-title":"Nature"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.cell.2012.06.045","article-title":"Small-Molecule Inhibition of BRDT for Male Contraception","volume":"150","author":"Matzuk","year":"2012","journal-title":"Cell"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e181","DOI":"10.1002\/ctm2.181","article-title":"BRD4 Regulates Self-Renewal Ability and Tumorigenicity of Glioma-Initiating Cells by Enrichment in the Notch1 Promoter Region","volume":"10","author":"Tao","year":"2020","journal-title":"Clin. Transl. Med."},{"key":"ref_65","first-page":"1415","article-title":"Genome-Wide Transcriptional Analysis of BRD4-Regulated Genes and Pathways in Human Glioma U251 Cells","volume":"52","author":"Du","year":"2018","journal-title":"Int. J. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00280-022-04483-7","article-title":"An Inhibitor of BRD4, GNE987, Inhibits the Growth of Glioblastoma Cells by Targeting C-Myc and S100A16","volume":"90","author":"Ma","year":"2022","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Ye, Y., Zhong, W., Qian, J., Zhang, J., Xu, T., Han, R., Han, J., Wang, C., Song, L., and Zeng, X. (2023). Comprehensive Analysis of the Prognosis and Immune Infiltrates for the BET Protein Family Reveals the Significance of BRD4 in Glioblastoma Multiforme. Front. Cell Dev. Biol., 11.","DOI":"10.3389\/fcell.2023.1042490"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41389-025-00551-8","article-title":"A HOTAIR-Associated Super-Enhancer Orchestrates Glioblastoma Malignancy via MEST","volume":"14","author":"Li","year":"2025","journal-title":"Oncogenesis"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1038\/s41388-025-03596-6","article-title":"BRD4 Inhibition Sensitizes Glioblastoma to Radiotherapy by Suppressing Super-Enhancer-Driven COL1A1","volume":"44","author":"Fan","year":"2025","journal-title":"Oncogene"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/s41419-022-05497-y","article-title":"BET Protein Inhibition Sensitizes Glioblastoma Cells to Temozolomide Treatment by Attenuating MGMT Expression","volume":"13","author":"Tancredi","year":"2022","journal-title":"Cell Death Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s11060-024-04889-8","article-title":"BRD4 Promotes Immune Escape of Glioma Cells by Upregulating PD-L1 Expression","volume":"171","author":"Liu","year":"2025","journal-title":"J. Neurooncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.tips.2025.09.006","article-title":"Targeting BRD4 Bromodomains and beyond: Exploring New Therapeutic Frontiers","volume":"47","author":"Zhang","year":"2025","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1039\/C8MD00198G","article-title":"Targeting Brd4 for Cancer Therapy: Inhibitors and Degraders","volume":"9","author":"Duan","year":"2018","journal-title":"MedChemComm"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"230","DOI":"10.4252\/wjsc.v6.i2.230","article-title":"Glioblastoma Stem Cells: Molecular Characteristics and Therapeutic Implications","volume":"6","author":"Bayin","year":"2014","journal-title":"World J. Stem Cells"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"7849890","DOI":"10.1155\/2016\/7849890","article-title":"Glioma Stem Cells: Signaling, Microenvironment, and Therapy","volume":"2016","author":"Liebelt","year":"2016","journal-title":"Stem Cells Int."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1101\/gad.261982.115","article-title":"Cancer Stem Cells in Glioblastoma","volume":"29","author":"Lathia","year":"2015","journal-title":"Genes Dev."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41525-019-0108-5","article-title":"Proneural and Mesenchymal Glioma Stem Cells Display Major Differences in Splicing and lncRNA Profiles","volume":"5","author":"Guardia","year":"2020","journal-title":"npj Genomic Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/tox.22873","article-title":"BRD4 Promotes Glioma Cell Stemness via Enhancing miR-142-5p-Mediated Activation of Wnt\/\u03b2-Catenin Signaling","volume":"35","author":"Wang","year":"2020","journal-title":"Environ. Toxicol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/s41419-020-03117-1","article-title":"BET Degrader Inhibits Tumor Progression and Stem-like Cell Growth via Wnt\/\u03b2-Catenin Signaling Repression in Glioma Cells","volume":"11","author":"Tian","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_80","first-page":"879","article-title":"Bromodomain Inhibitor Jq1 Induces Cell Cycle Arrest and Apoptosis of Glioma Stem Cells through the VEGF\/PI3K\/AKT Signaling Pathway","volume":"55","author":"Wen","year":"2019","journal-title":"Int. J. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1158\/1078-0432.CCR-16-0048","article-title":"Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0\/I Trial","volume":"22","author":"Xu","year":"2016","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1038\/s41467-018-05373-4","article-title":"A Novel Enhancer Regulates MGMT Expression and Promotes Temozolomide Resistance in Glioblastoma","volume":"9","author":"Chen","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2409753","DOI":"10.1002\/advs.202409753","article-title":"BRD4 Degradation Enhanced Glioma Sensitivity to Temozolomide by Regulating Notch1 via Glu-Modified GSH-Responsive Nanoparticles","volume":"11","author":"Yi","year":"2024","journal-title":"Adv. Sci."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Gargano, D., Segatto, M., and Di Bartolomeo, S. (2023). Regulation of Cell Plasticity by Bromodomain and Extraterminal Domain (BET) Proteins: A New Perspective in Glioblastoma Therapy. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24065665"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1158\/1535-7163.MCT-20-0037","article-title":"A Combination of BRD4 and HDAC3 Inhibitors Synergistically Suppresses Glioma Stem Cell Growth by Blocking GLI1\/IL6\/STAT3 Signaling Axis","volume":"19","author":"Wang","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Ferri, A., Stagni, V., and Baril\u00e0, D. (2020). Targeting the DNA Damage Response to Overcome Cancer Drug Resistance in Glioblastoma. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21144910"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.dnarep.2019.04.007","article-title":"DNA Repair in Personalized Brain Cancer Therapy with Temozolomide and Nitrosoureas","volume":"78","author":"Kaina","year":"2019","journal-title":"DNA Repair"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/nrc2342","article-title":"DNA Repair Pathways as Targets for Cancer Therapy","volume":"8","author":"Helleday","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.celrep.2017.12.078","article-title":"BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate Cancer","volume":"22","author":"Li","year":"2018","journal-title":"Cell Rep."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.molcel.2014.05.018","article-title":"Chromatin Reader Brd4 Functions in Ig Class Switching as a Repair Complex Adaptor of Nonhomologous End-Joining","volume":"55","author":"Stanlie","year":"2014","journal-title":"Mol. Cell"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1126\/science.1076182","article-title":"53BP1, a Mediator of the DNA Damage Checkpoint","volume":"298","author":"Wang","year":"2002","journal-title":"Science"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1038\/s41388-018-0194-3","article-title":"BRD4 Facilitates Replication Stress-Induced DNA Damage Response","volume":"37","author":"Zhang","year":"2018","journal-title":"Oncogene"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/nature12147","article-title":"The Bromodomain Protein Brd4 Insulates Chromatin from DNA Damage Signalling","volume":"498","author":"Floyd","year":"2013","journal-title":"Nature"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"13427","DOI":"10.1038\/ncomms13427","article-title":"In Silico Pathway Activation Network Decomposition Analysis (iPANDA) as a Method for Biomarker Development","volume":"7","author":"Ozerov","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1158\/1535-7163.MCT-16-0141","article-title":"AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies","volume":"15","author":"Rhyasen","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/ejh.13525","article-title":"Targeting Both BET and CBP\/EP300 Proteins with the Novel Dual Inhibitors NEO2734 and NEO1132 Leads to Anti-Tumor Activity in Multiple Myeloma","volume":"106","author":"Ryan","year":"2021","journal-title":"Eur. J. Haematol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1812878","DOI":"10.1080\/15592324.2020.1812878","article-title":"The Function of the WRI1-TCP4 Regulatory Module in Lipid Biosynthesis","volume":"15","author":"Kong","year":"2020","journal-title":"Plant Signal. Behav."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"611","DOI":"10.4161\/epi.27906","article-title":"BET Bromodomain Proteins Are Required for Glioblastoma Cell Proliferation","volume":"9","author":"Pastori","year":"2014","journal-title":"Epigenetics"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"23370","DOI":"10.1038\/s41598-021-02584-6","article-title":"The Novel BET Inhibitor UM-002 Reduces Glioblastoma Cell Proliferation and Invasion","volume":"11","author":"Jermakowicz","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"a026674","DOI":"10.1101\/cshperspect.a026674","article-title":"Targeting Cancer Cells with BET Bromodomain Inhibitors","volume":"7","author":"Xu","year":"2017","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nature16508","article-title":"Response and Resistance to BET Bromodomain Inhibitors in Triple-Negative Breast Cancer","volume":"529","author":"Shu","year":"2016","journal-title":"Nature"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"pkz093","DOI":"10.1093\/jncics\/pkz093","article-title":"Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors","volume":"4","author":"Hann","year":"2020","journal-title":"JNCI Cancer Spectr."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nature14888","article-title":"BET Inhibitor Resistance Emerges from Leukaemia Stem Cells","volume":"525","author":"Fong","year":"2015","journal-title":"Nature"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"117134","DOI":"10.1016\/j.bmc.2022.117134","article-title":"Design, Synthesis, and Biological Evaluation of BRD4 Degraders","volume":"78","author":"Ding","year":"2023","journal-title":"Bioorg. Med. Chem."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Lu, Y., Sun, D., Xiao, D., Shao, Y., Su, M., Zhou, Y., Li, J., Zhu, S., and Lu, W. (2021). Design, Synthesis, and Biological Evaluation of HDAC Degraders with CRBN E3 Ligase Ligands. Molecules, 26.","DOI":"10.3390\/molecules26237241"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1080\/14756366.2022.2081164","article-title":"PROTACs for BRDs Proteins in Cancer Therapy: A Review","volume":"37","author":"Wang","year":"2022","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.chembiol.2015.05.009","article-title":"Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4","volume":"22","author":"Lu","year":"2015","journal-title":"Chem. Biol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1080\/13543776.2024.2400166","article-title":"An Updated Patent Review of BRD4 Degraders","volume":"34","author":"Ma","year":"2024","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1021\/acs.jmedchem.6b01816","article-title":"Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression","volume":"61","author":"Zhou","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1021\/acschembio.5b00216","article-title":"Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4","volume":"10","author":"Zengerle","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Archasappawat, S., Jacques, J., Lee, E., and Hwang, C.-I. (2025). BRD2 Upregulation as a Pan-Cancer Adaptive Resistance Mechanism to BET Inhibition. bioRxiv, bioRxiv:2025.08.30.673282.","DOI":"10.1101\/2025.08.30.673282"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s40364-025-00788-w","article-title":"Epigenetic Regulation of Histone Modifications in Glioblastoma: Recent Advances and Therapeutic Insights","volume":"13","author":"Zhang","year":"2025","journal-title":"Biomark. Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1093\/neuonc\/noaf169","article-title":"BRD2 Bromodomain-Mediated Regulation of Cell State Plasticity Modulates Therapy Response in Glioblastoma","volume":"27","author":"Vadla","year":"2025","journal-title":"Neuro-Oncology"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature14898","article-title":"Transcriptional Plasticity Promotes Primary and Acquired Resistance to BET Inhibition","volume":"525","author":"Rathert","year":"2015","journal-title":"Nature"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.ccell.2018.11.005","article-title":"Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling","volume":"34","author":"Iniguez","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"45643","DOI":"10.18632\/oncotarget.17314","article-title":"Ubenimex Enhances Brd4 Inhibition by Suppressing HEXIM1 Autophagic Degradation and Suppressing the Akt Pathway in Glioma Cells","volume":"8","author":"Han","year":"2017","journal-title":"Oncotarget"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/s41419-019-2120-1","article-title":"BET and Aurora Kinase A Inhibitors Synergize against MYCN-Positive Human Glioblastoma Cells","volume":"10","author":"Drews","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"9284","DOI":"10.1038\/s41598-024-60031-8","article-title":"RAPID Resistance to BET Inhibitors Is Mediated by FGFR1 in Glioblastoma","volume":"14","author":"Jermakowicz","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.celrep.2016.06.091","article-title":"Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer","volume":"16","author":"Kurimchak","year":"2016","journal-title":"Cell Rep."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.celrep.2015.03.037","article-title":"Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains","volume":"11","author":"Stuhlmiller","year":"2015","journal-title":"Cell Rep."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s41416-019-0724-y","article-title":"Targeting BRD\/BET Proteins Inhibits Adaptive Kinome Upregulation and Enhances the Effects of BRAF\/MEK Inhibitors in Melanoma","volume":"122","author":"Tiago","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Rynkeviciene, R., Simiene, J., Strainiene, E., Stankevicius, V., Usinskiene, J., Miseikyte Kaubriene, E., Meskinyte, I., Cicenas, J., and Suziedelis, K. (2018). Non-Coding RNAs in Glioma. Cancers, 11.","DOI":"10.3390\/cancers11010017"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1038\/bjc.2013.233","article-title":"Long Noncoding RNAs and the Genetics of Cancer","volume":"108","author":"Cheetham","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Shi, Y., Wang, Y., Luan, W., Wang, P., Tao, T., Zhang, J., Qian, J., Liu, N., and You, Y. (2014). Long Non-Coding RNA H19 Promotes Glioma Cell Invasion by Deriving miR-675. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0086295"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/nature08975","article-title":"Long Non-Coding RNA HOTAIR Reprograms Chromatin State to Promote Cancer Metastasis","volume":"464","author":"Gupta","year":"2010","journal-title":"Nature"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1038\/onc.2012.193","article-title":"HOTAIR Is a Negative Prognostic Factor and Exhibits Pro-Oncogenic Activity in Pancreatic Cancer","volume":"32","author":"Kim","year":"2013","journal-title":"Oncogene"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1093\/neuonc\/not131","article-title":"HOTAIR, a Cell Cycle-Associated Long Noncoding RNA and a Strong Predictor of Survival, Is Preferentially Expressed in Classical and Mesenchymal Glioma","volume":"15","author":"Zhang","year":"2013","journal-title":"Neuro-Oncology"},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"DeSouza, P.A., Qu, X., Chen, H., Patel, B., Maher, C.A., and Kim, A.H. (2021). Long, Noncoding RNA Dysregulation in Glioblastoma. Cancers, 13.","DOI":"10.3390\/cancers13071604"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"8326","DOI":"10.1073\/pnas.1424220112","article-title":"The Bromodomain Protein BRD4 Controls HOTAIR, a Long Noncoding RNA Essential for Glioblastoma Proliferation","volume":"112","author":"Pastori","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.nbd.2009.07.030","article-title":"Structure and Function of the Blood-Brain Barrier","volume":"37","author":"Abbott","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Ter Linden, E., Abels, E.R., van Solinge, T.S., Neefjes, J., and Broekman, M.L.D. (2024). Overcoming Barriers in Glioblastoma-Advances in Drug Delivery Strategies. Cells, 13.","DOI":"10.3390\/cells13120998"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/neuonc\/nox175","article-title":"Is the Blood-Brain Barrier Really Disrupted in All Glioblastomas? A Critical Assessment of Existing Clinical Data","volume":"20","author":"Sarkaria","year":"2018","journal-title":"Neuro-Oncology"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1093\/neuonc\/noac263","article-title":"Trotabresib, an Oral Potent Bromodomain and Extraterminal Inhibitor, in Patients with High-Grade Gliomas: A Phase I, \u201cWindow-of-Opportunity\u201d Study","volume":"25","author":"Moreno","year":"2023","journal-title":"Neuro-Oncology"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"123785","DOI":"10.1016\/j.biomaterials.2025.123785","article-title":"Restoration of P53 mRNA Combined with BRD4 Silencing by Brain Targeted Nanocapsules Achieves Effective Combinatorial Treatment of Glioblastoma","volume":"327","author":"Sang","year":"2025","journal-title":"Biomaterials"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/neuonc\/noy002","article-title":"Females Have the Survival Advantage in Glioblastoma","volume":"20","author":"Ostrom","year":"2018","journal-title":"Neuro-Oncology"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/2042-6410-3-3","article-title":"Why Does Jack, and Not Jill, Break His Crown? Sex Disparity in Brain Tumors","volume":"3","author":"Sun","year":"2012","journal-title":"Biol. Sex Differ."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"e2017148118","DOI":"10.1073\/pnas.2017148118","article-title":"Brd4-Bound Enhancers Drive Cell-Intrinsic Sex Differences in Glioblastoma","volume":"118","author":"Kfoury","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/biolre\/ioaa043","article-title":"Metabolism of JQ1, an Inhibitor of Bromodomain and Extra Terminal Bromodomain Proteins, in Human and Mouse Liver Microsomes","volume":"103","author":"Li","year":"2020","journal-title":"Biol. Reprod."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"117418","DOI":"10.1016\/j.bcp.2025.117418","article-title":"Bromodomain Containing Protein 4 (BRD4) and Cancer Therapy: A Glimpse at Dual-Target Drug Development","volume":"242","author":"Li","year":"2025","journal-title":"Biochem. Pharmacol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/s41418-022-00977-2","article-title":"BH3 Mimetic Drugs Cooperate with Temozolomide, JQ1 and Inducers of Ferroptosis in Killing Glioblastoma Multiforme Cells","volume":"29","author":"Moujalled","year":"2022","journal-title":"Cell Death Differ."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1002\/ijc.30256","article-title":"OTX015 (MK-8628), a Novel BET Inhibitor, Displays in Vitro and in Vivo Antitumor Effects Alone and in Combination with Conventional Therapies in Glioblastoma Models","volume":"139","author":"Odore","year":"2016","journal-title":"Int. J. Cancer"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1039\/D5BM00443H","article-title":"Polymer-Engineered PROTAC Nanovehicles Amplify Synergistic Effects with Temozolomide by BRD4 Degradation","volume":"13","author":"Guo","year":"2025","journal-title":"Biomater. Sci."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"5345","DOI":"10.1074\/jbc.RA117.000443","article-title":"Nitric Oxide Antagonism to Glioblastoma Photodynamic Therapy and Mitigation Thereof by BET Bromodomain Inhibitor JQ1","volume":"293","author":"Fahey","year":"2018","journal-title":"J. Biol. Chem."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.freeradbiomed.2019.04.013","article-title":"Upstream Signaling Events Leading to Elevated Production of Pro-Survival Nitric Oxide in Photodynamically-Challenged Glioblastoma Cells","volume":"137","author":"Fahey","year":"2019","journal-title":"Free Radic. Biol. Med."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/php.12636","article-title":"Antagonistic Effects of Endogenous Nitric Oxide in a Glioblastoma Photodynamic Therapy Model","volume":"92","author":"Fahey","year":"2016","journal-title":"Photochem. Photobiol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1016\/j.ymthe.2021.05.019","article-title":"BRD4 Inhibition Boosts the Therapeutic Effects of Epidermal Growth Factor Receptor-Targeted Chimeric Antigen Receptor T Cells in Glioblastoma","volume":"29","author":"Xia","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1016\/j.apsb.2022.02.009","article-title":"A BRD4 PROTAC Nanodrug for Glioma Therapy via the Intervention of Tumor Cells Proliferation, Apoptosis and M2 Macrophages Polarization","volume":"12","author":"Yang","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Pu, Y., and Ji, Q. (2022). Tumor-Associated Macrophages Regulate PD-1\/PD-L1 Immunosuppression. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.874589"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"2307747","DOI":"10.1002\/advs.202307747","article-title":"Sequential Inhibition of PARP and BET as a Rational Therapeutic Strategy for Glioblastoma","volume":"11","author":"Peng","year":"2024","journal-title":"Adv. Sci."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.7150\/thno.92526","article-title":"Degraders in Epigenetic Therapy: PROTACs and Beyond","volume":"14","author":"Dai","year":"2024","journal-title":"Theranostics"},{"key":"ref_151","first-page":"e54101","article-title":"Assessment of the Efficacy of Circulating Tumor Cells by Liquid Biopsy in the Diagnosis and Prediction of Tumor Behavior of Gliomas: A Systematic Review","volume":"16","author":"Eugene","year":"2024","journal-title":"Cureus"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s10571-024-01515-z","article-title":"Application of Circulating Tumor DNA in the Auxiliary Diagnosis and Prognosis Prediction of Glioma","volume":"45","author":"Lu","year":"2024","journal-title":"Cell. Mol. Neurobiol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41416-019-0603-6","article-title":"Circulating Biomarkers in Patients with Glioblastoma","volume":"122","author":"Kulasinghe","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Piazza, A., Rosa, P., Ricciardi, L., Mangraviti, A., Pacini, L., Calogero, A., Raco, A., and Miscusi, M. (2022). Circulating Exosomal-DNA in Glioma Patients: A Quantitative Study and Histopathological Correlations-A Preliminary Study. Brain Sci., 12.","DOI":"10.3390\/brainsci12040500"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"21577","DOI":"10.1021\/acs.jmedchem.4c02516","article-title":"Discovery of the First BRD4 Second Bromodomain (BD2)-Selective Inhibitors","volume":"67","author":"Li","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1007\/s11030-024-11011-7","article-title":"AI-DPAPT: A Machine Learning Framework for Predicting PROTAC Activity","volume":"29","author":"Abouzied","year":"2025","journal-title":"Mol. Divers."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s43556-023-00127-1","article-title":"Targeting Bromodomain-Containing Proteins: Research Advances of Drug Discovery","volume":"4","author":"Pan","year":"2023","journal-title":"Mol. Biomed."},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Grzegorzewski, J., Michalak, M., Wo\u0142oszczuk, M., Bulicz, M., and Majchrzak-Celi\u0144ska, A. (2025). Nanotherapy of Glioblastoma-Where Hope Grows. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26051814"},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Manzotti, G., Ciarrocchi, A., and Sancisi, V. (2019). Inhibition of BET Proteins and Histone Deacetylase (HDACs): Crossing Roads in Cancer Therapy. Cancers, 11.","DOI":"10.3390\/cancers11030304"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.18632\/oncotarget.3551","article-title":"Inhibition of BET Bromodomains as a Therapeutic Strategy for Cancer Drug Discovery","volume":"6","author":"Fu","year":"2015","journal-title":"Oncotarget"},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Deeney, J.T., Belkina, A.C., Shirihai, O.S., Corkey, B.E., and Denis, G.V. (2016). BET Bromodomain Proteins Brd2, Brd3 and Brd4 Selectively Regulate Metabolic Pathways in the Pancreatic \u03b2-Cell. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0151329"},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Zhang, K., Gao, L., Wang, J., Chu, X., Zhang, Z., Zhang, Y., Fang, F., Tao, Y., Li, X., and Tian, Y. (2022). A Novel BRD Family PROTAC Inhibitor dBET1 Exerts Great Anti-Cancer Effects by Targeting c-MYC in Acute Myeloid Leukemia Cells. Pathol. Oncol. Res. POR, 28.","DOI":"10.3389\/pore.2022.1610447"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"8222","DOI":"10.1021\/acs.jmedchem.3c00520","article-title":"Precise Conformational Control Yielding Highly Potent and Exceptionally Selective BRD4 Degraders with Strong Antitumor Activity","volume":"66","author":"Hu","year":"2023","journal-title":"J. Med. Chem."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/5\/2268\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T10:27:19Z","timestamp":1772447239000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/5\/2268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,28]]},"references-count":163,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["ijms27052268"],"URL":"https:\/\/doi.org\/10.3390\/ijms27052268","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,28]]}}}